Navigation Links
Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors

READING, Pa., Sept. 13 /PRNewswire-FirstCall/ -- Arrow International, Inc. (Nasdaq: ARRO) today sent another letter to shareholders urging them to vote today on the WHITE proxy card for its planned $45.50 merger with Teleflex Incorporated (NYSE: TFX) and to re-elect the Arrow Board of Directors, who are committed to completing the Teleflex transaction and delivering $45.50 per share of Arrow common stock to shareholders once the merger is consummated. The Annual Meeting is on September 20, 2007.

The text of the letter follows:

Dear Fellow Arrow Shareholder:

Your vote in support of the merger on the WHITE proxy card is very important

With the Annual Meeting just a week away on September 20, we urge you to vote your WHITE proxy card NOW in support of our $45.50 per share merger with Teleflex. By voting the WHITE proxy card, and voting to approve this transaction and re-elect all of the members of your current Board of Directors, you can help assure that the merger is completed and that you will receive your cash payment.

Your vote to re-elect Arrow's director-nominees is also very important

If you are in favor of the Teleflex merger, we believe it is in your best interests to vote to re-elect your current Board of Directors. These directors are experienced, dedicated and fully committed to completing the Teleflex merger and protecting the interests of all Arrow shareholders. Your current Board of Directors initiated the strategic alternatives process that resulted in the $45.50 per share cash offer from Teleflex.

Do NOT add risk by voting for the McNeil Trust

There is no need to add uncertainty to the merger closing process by electing new directors, as the McNeil Trust is attempting to do. The McNeil Trust opposed the strategic alternatives process from the beginning and voiced support for the merger only after the transaction was publicly announced. There is a difference between being committed to a transaction and merely agreeing to vote for it. We do not think it is in your best interest to allow nominees of a shareholder who is not committed to completing this merger handle any issues that may arise between the approval of the merger agreement and the closing of the transaction. We believe the McNeil Trust's nominees are not the best option for shareholders. We believe their slate presents added risk to the transaction, and in the unlikely event the merger is not consummated, the Trust's slate offers only a return to the disappointments that existed when the current Board of Directors decided to explore strategic alternatives. We strongly urge you NOT to sign or return any blue proxy cards to the McNeil Trust.

Please vote the WHITE proxy card today

If your shares are held by your brokerage firm or bank, you must provide them with instructions on how to vote on your behalf or they will be unable to vote your shares on certain issues, including the adoption of the merger agreement. Given that time is short, we encourage you to follow the instructions on the enclosed form to vote by telephone or Internet.

If you have any questions or would like assistance in voting your shares of Arrow common stock, please call our proxy solicitor, Morrow & Co., Inc., toll-free at 1-800-662-5200.

Sincerely yours,

Philip B. Fleck

President and Chief Executive Officer

R. James Macaleer

Chairman of the Board of Directors

About Arrow

Arrow develops, manufactures and markets a broad range of clinically advanced, disposable catheters and related products for critical and cardiac care. The company's products are used primarily by anesthesiologists, critical care specialists, surgeons, emergency and trauma physicians, cardiologists, interventional radiologists and other healthcare providers. Arrow's news releases and other company information can be found on the World Wide Web at . Arrow's common stock trades on the NASDAQ Global Select Market(TM) under the symbol ARRO.

Additional Information

In connection with the proposed acquisition of Arrow by Teleflex Incorporated and Arrow's 2007 Annual Meeting of Shareholders, Arrow filed a definitive proxy statement with the SEC, on August 24, 2007 and will be filing other documents with the SEC. Arrow has furnished a definitive proxy statement to its shareholders, together with a WHITE proxy card. Arrow shareholders are strongly advised to carefully read Arrow's definitive proxy statement. Shareholders may obtain the definitive proxy statement on file with the SEC and any other documents filed by Arrow with the SEC for free at the internet website maintained by the SEC at . Shareholders may obtain free copies of the definitive proxy statement and any amendments and supplements to the definitive proxy statement at Arrow's website at or by writing to Arrow International, Inc., 2400 Bernville Road, Reading, Pennsylvania 19605. In addition, copies of Arrow's proxy materials may be requested by contacting our proxy solicitor, Morrow & Co. at (800) 662-5200 toll-free or by writing to Morrow & Co., 470 West Avenue, Stamford, CT 06902. Arrow and its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Additional information regarding the names, affiliations and interests of individuals who are participants in the solicitation of proxies of Arrow's shareholders is available in Arrow's definitive proxy statement filed with the SEC on August 24, 2007.

SOURCE Arrow International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Creating brain cells from bone marrow
2. Bone marrow transplants for limbs
3. Bone marrow stem cells may help repair cardiac tissues
4. Bones repair themselves with bone marrow cells
5. Bone Marrow Cells Help Heart Attack Patients
6. Bone Marrow Cells Could Yield A New Lease of Life
7. Stem Cells From Bone Marrow Found To Improve Cardiac Functioning After A Heart Attack
8. Umbilical Cord Blood Offers Hope For Patients Who Require Bone Marrow Transplants
9. Mouth wash samples to predict bone marrow transplant results
10. Stents That Release Medication To Check Artery Narrowing
11. Measuring disseminated cancer cells in bone marrow - valuable tool for detecting early breast cancer metastasis
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Chiropractic student Katie ... (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester student in the university’s ... Cleveland III on October 16. , “Katie is very excited and greatly appreciative ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... award for its exceptional customer service: the TrustDale certification. The award recognizes good ... Baltimore stone honing , tile and grout, and hard surface restoration company ...
(Date:11/24/2015)... ... ... Bibliomotion is thrilled to announce the launch of UNCONVENTIONAL ... Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health System (November ... of patients and their families, shaped my desire to improve the system of care. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Kevin Day, local family ... community stress less this holiday season. During the Indiana winter months, Vitamin D ... and the team at AlignLife want to help provide the tools needed to combat ...
(Date:11/24/2015)... ... ... Peck’s mother wondered if she was a descendant of Samuel Fuller, a passenger on the ... for information, Don and his aunt discovered that she was not, in fact, related to ... Don’s father who was descended from not one, but four passengers on the famed ship ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015  Array BioPharma Inc. (Nasdaq: ARRY ... Ron Squarer , will present at the ... The public is welcome to participate in the ... website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron Squarer, ... p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... , 24 de noviembre de 2015 /PRNewswire/ ... Breathing Pacemaker System, se complace anunciar el nombramiento ... consultor clínico.   ... -   --> ... un fisiólogo y consultor en neonatología y cardiología ...
(Date:11/24/2015)... India , November 24, 2015 ... market research report "Spine Biologics Market by Product Type (Bone ... (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End ... MarketsandMarkets, the global market was valued at $1.90 Billion in ... at a CAGR of 4.4% during the forecast period of ...
Breaking Medicine Technology: